GlassScriptPhysician profile
John J Pantuosco
NPI 1619327913
$12,128.59
in general payments reported to CMS, 2019-2025
19 companies · $711 in 2025
The $711 reported for 2025 was more than what 84% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.53 · 2021: $444 · 2022: $257 · 2023: $2,505 · 2024: $8,196 · 2025: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,000 · Food and Beverage: $3,532 · Travel and Lodging: $880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,000.00 |
| Food and Beverage | $3,532.06 |
| Travel and Lodging | $879.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $7,503.85 | 2023-2024 | Mild Device Kit |
| Relievant Medsystems, INC. | $1,601.80 | 2022-2023 | Intracept |
| Nevro Corp. | $739.37 | 2021-2024 | Senza |
| Spr Therapeutics, INC | $553.09 | 2023-2025 | Sprint Pns System |
| Boston Scientific Corporation | $466.93 | 2022-2025 | Intracept, General - Pain Management |
| Painteq LLC | $377.09 | 2022-2024 | Painteq |
| Medtronic, INC. | $246.46 | 2023-2025 | Intellis Adaptivestim, Inceptiv |
| Saluda Medical Americas, INC. | $203.49 | 2025 | Evoke |
| Curonix LLC | $124.79 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Abbvie INC. | $84.90 | 2022-2025 | |
| Lundbeck LLC | $49.13 | 2024-2025 | Vyepti |
| Pacira Pharmaceuticals Incorporated | $34.03 | 2024 | Zilretta, Iovera |
| Azurity Pharmaceuticals, INC. | $29.72 | 2025 | Horizant |
| Merck Sharp & Dohme LLC | $24.86 | 2023 | Bridion |
| Averitas Pharma INC. | $24.45 | 2023 | Qutenza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $17.60 | 2025 | |
| Depuy Synthes Sales INC. | $15.79 | 2024 | Orthovisc, Monovisc |
| Bioventus LLC | $15.71 | 2023 | Durolane |
| Avanir Pharmaceuticals, INC. | $15.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Pantuosco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.